Literature DB >> 8254391

Clinical evaluation of thallium-201 SPECT in supratentorial gliomas: relationship to histologic grade, prognosis and proliferative activities.

N Oriuchi1, M Tamura, T Shibazaki, C Ohye, N Watanabe, M Tateno, K Tomiyoshi, T Hirano, T Inoue, K Endo.   

Abstract

We performed 201Tl SPECT and cell kinetic studies on 28 presurgical patients with supratentorial gliomas by administering bromodeoxyuridine (BUdR). All patients had surgery and had follow-up for more than 25 mo. In patients with grade IV glioma (198.1% +/- 32.8%, n = 10), the 201Tl index, expressed as the count rate of the tumor site to the count rate over the contralateral normal region, was significantly higher than that in patients with grade III glioma (140.5% +/- 15.1%, n = 4, p < 0.01) or low-grade glioma (104.1% +/- 22.6%, n = 14, p < 0.001). A significant correlation was observed between the 201Tl index and BUdR-positive cells in excised tumor specimens (r = 0.67, p < 0.001). The 201Tl index of the 12 patients who died was higher than those who survived (173.2% versus 122.4%, p < 0.01). These results show the clinical utility of 201Tl brain SPECT in imaging supratentorial glioma and that the 201Tl index is representative of proliferative activity of the tumor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8254391

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

1.  Relationship between thallium-201 uptake by supratentorial glioblastomas and their morphological characteristics on magnetic resonance imaging.

Authors:  M Ricci; P Pantano; A Pierallini; D Di Stefano; A Santoro; L Bozzao; G L Lenzi
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Intense and prolonged Tl-201 accumulation in a slow growing bronchioloalveolar carcinoma.

Authors:  S Kinuya; S Takahashi; M Saito; Y Tofuku; T Michigishi; N Tonami
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

3.  Clinical significance of thallium-201 SPECT after postoperative radiotherapy in patients with glioblastoma multiforme.

Authors:  Gyo Iida; Kazuhiko Ogawa; Shogo Ishiuchi; Itaru Chiba; Takashi Watanabe; Naofumi Katsuyama; Yoshihiko Yoshii; Sadayuki Murayama
Journal:  J Neurooncol       Date:  2010-09-02       Impact factor: 4.130

Review 4.  Where are we with nuclear medicine in pediatrics?

Authors:  H R Nadel
Journal:  Eur J Nucl Med       Date:  1995-12

Review 5.  Techniques to assess the proliferative potential of brain tumors.

Authors:  Alfredo Quiñones-Hinojosa; Nader Sanai; Justin S Smith; Michael W McDermott
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

6.  (99m)Tc-Tetrofosmin brain SPECT in the assessment of meningiomas-correlation with histological grade and proliferation index.

Authors:  Andreas D Fotopoulos; George A Alexiou; Ann Goussia; Athanasios Papadopoulos; Athanasios P Kyritsis; Konstantinos S Polyzoidis; Spyridon Voulgaris; Spyridon Tsiouris
Journal:  J Neurooncol       Date:  2008-05-06       Impact factor: 4.130

7.  The role of 201Tl scintigraphy in evaluating proliferative activity in thyroid neoplasms.

Authors:  K Nakada; C Katoh; K Kanegae; E Tsukamoto; K Itoh; M Furudate; N Tamaki
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

8.  201TL SPECT for evaluating head and neck cancer.

Authors:  S Nagamachi; H Hoshi; S Jinnouchi; T Ohnishi; L G Flores; S Futami; H Nakahara; K Watanabe
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

9.  Use of 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas.

Authors:  V Vallejos; C Balaña; M Fraile; Y Roussos; J Capellades; P Cuadras; R Ballester; A Ley; A Arellano; R Rosell
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

10.  (201)Tl-SPECT in low-grade gliomas: diagnostic accuracy in differential diagnosis between tumour recurrence and radionecrosis.

Authors:  Manuel Gómez-Río; Dolores Martínez Del Valle Torres; Antonio Rodríguez-Fernández; José Manuel Llamas-Elvira; Simeón Ortega Lozano; Carlos Ramos Font; Escarlata López Ramírez; Majed Katati
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.